The glutathione system in alkylator resistance.
Hamilton
David
D
Department of Pharmacology and Therapeutics, McGill University, Lady Davis Institute for Medical Research, Sir Mortimer B Davis-Jewish General Hospital, Montréal, Québec, Canada.
Fotouhi-Ardakani
Nasser
N
Batist
Gerald
G
D000477:Alkylating Agents / Q000494:pharmacology*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D019328:Buthionine Sulfoximine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005721:Glutamate-Cysteine Ligase / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism*; D005981:Glutathione Synthase / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use; D013871:Thiones; D013876:Thiophenes
D000477:Alkylating Agents; D016588:Anticarcinogenic Agents; D004791:Enzyme Inhibitors; D011719:Pyrazines; D013871:Thiones; D013876:Thiophenes; D019328:Buthionine Sulfoximine; C026209:oltipraz; D005721:Glutamate-Cysteine Ligase; D005981:Glutathione Synthase; D005978:Glutathione; D004976:Ethacrynic Acid